Anavex Life Sciences Corp
AVXL10.020USD
-0.240-2.34%
Market hours （ET）Quotes delayed by 15 min
855.83MMarket Cap
LossP/E TTM
More Details of Anavex Life Sciences Corp Company
Anavex Life Sciences Corp. is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system (CNS) diseases with high unmet need. The Company analyzes genomic data from clinical trials to identify biomarkers, which it uses in the analysis of its clinical trials. Its focus is on developing treatments for Alzheimer’s disease, Parkinson’s disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other CNS disorders. It has two core programs and two seed programs. ANAVEX 2-73 is being developed as an oral liquid once-daily formulation for rare diseases such as Rett syndrome as well as an oral once-daily capsule formulation for diseases such as Alzheimer’s disease. ANAVEX 3-71 is a CNS-penetrable potential disease-modifying treatment for cognitive impairments. Its other candidates include ANAVEX 1-41, ANAVEX 1066 and ANAVEX 1037.
Company Info
Ticker SymbolAVXL
Company nameAnavex Life Sciences Corp
IPO dateApr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
Number of employees42
Security typeOrdinary Share
Fiscal year-endApr 13
Address630 5Th Avenue
CityNEW YORK
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code10111
Phone18446893939
Websitehttps://www.anavex.com
Ticker SymbolAVXL
IPO dateApr 13, 2006
CEODr. Christopher U. Missling, Ph.D.
Company Executives
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Dr. Steffen Thomas, Ph.D.
Dr. Steffen Thomas, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Christopher U. Missling, Ph.D.
Dr. Christopher U. Missling, Ph.D.
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
1.47M
--
Mr. Athanasios (Tom) Skarpelos
Mr. Athanasios (Tom) Skarpelos
Independent Director
Independent Director
1.31M
--
Ms. Sandra Boenisch, CPA
Ms. Sandra Boenisch, CPA
Principal Financial Officer, Treasurer
Principal Financial Officer, Treasurer
22.96K
--
Dr. Claus van Der Velden, Ph.D.
Dr. Claus van Der Velden, Ph.D.
Independent Director
Independent Director
--
--
Dr. Peter Donhauser, M.D.
Dr. Peter Donhauser, M.D.
Independent Director
Independent Director
--
--
Ms. Jiong Ma, Ph.D.
Ms. Jiong Ma, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Global Advisors (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
Other
78.96%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
7.24%
The Vanguard Group, Inc.
5.92%
State Street Global Advisors (US)
3.43%
Geode Capital Management, L.L.C.
2.35%
Two Sigma Investments, LP
2.09%
Other
78.96%
Shareholder Types
Shareholders
Proportion
Investment Advisor
23.80%
Investment Advisor/Hedge Fund
9.48%
Individual Investor
3.31%
Hedge Fund
3.04%
Research Firm
1.07%
Bank and Trust
0.83%
Pension Fund
0.22%
Insurance Company
0.04%
Other
58.22%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
355
34.98M
40.98%
-162.00K
2025Q1
362
35.10M
41.13%
+789.16K
2024Q4
351
32.45M
38.14%
-89.26K
2024Q3
337
29.80M
35.14%
-2.92M
2024Q2
337
29.64M
35.02%
-6.78M
2024Q1
332
34.88M
42.48%
+4.38M
2023Q4
335
28.85M
35.15%
-996.59K
2023Q3
331
28.07M
34.33%
-2.23M
2023Q2
335
28.30M
35.04%
-4.91M
2023Q1
340
29.94M
37.61%
-3.19M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
5.98M
7%
+20.29K
+0.34%
Mar 31, 2025
The Vanguard Group, Inc.
4.88M
5.72%
+202.97K
+4.34%
Mar 31, 2025
State Street Global Advisors (US)
3.21M
3.77%
+802.33K
+33.26%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.96M
2.3%
+89.89K
+4.79%
Mar 31, 2025
Two Sigma Investments, LP
1.37M
1.6%
+100.80K
+7.95%
Mar 31, 2025
Missling (Christopher U)
1.47M
1.72%
--
--
Apr 25, 2025
Skarpelos (Athanasios)
1.31M
1.53%
--
--
Apr 25, 2025
Northwest Asset Management
1.00M
1.17%
+87.30K
+9.56%
Mar 31, 2025
Invesco Capital Management LLC
515.07K
0.6%
-77.48K
-13.08%
Mar 31, 2025
Northern Trust Investments, Inc.
674.75K
0.79%
-26.63K
-3.80%
Mar 31, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
